Board hears evidence of pharmacy barriers to buprenorphine access; members back education and inter‑board outreach

Physicians, hospital navigators and addiction specialists told the California State Board of Pharmacy on Feb. 6 that fragile pharmacy practices and outdated guidance can block access to buprenorphine, a life-saving medication for opioid use disorder.

Presenters from California Bridge, UC Davis and the American Society of Addiction Medicine described repeated incidents in which patients left emergency departments with buprenorphine prescriptions but could not get the medication filled at community pharmacies. Reported obstacles included pharmacies denying early refills, treating buprenorphine under the same scrutiny as full-agonist opioids, stock shortages and difficulty contacting prescribers for confirmation.

Tommy Trevino, a UC Davis substance-use navigator, described a patient encounter in which staff at a pharmacy threatened to call police rather than dispense a prescription for buprenorphine to a person in withdrawal. Presenters said that experience—and others like it—contributes to treatment gaps and repeated emergency visits. A survey presented by California Bridge staff found that one-third of emergency-department navigators reported pharmacy barriers as a major issue in linking patients to outpatient treatment.

Clinicians and advocates urged the board to consider several steps: revise or clarify the board's guidance on "red flags" so it distinguishes buprenorphine from other opioids, encourage pharmacies to attempt direct contact with prescribers before refusing a fill, and create clear expectations for documentation of contact attempts. They also recommended pharmacist education and collaborations between the Board of Pharmacy, the Medical Board and other licensing entities so prescribers and pharmacists have clearer, HIPAA-compliant lines of communication for resolving "corresponding responsibility" questions.

Board members voiced support for further work. Several members asked staff to place pharmacy safety, communication pathways and guidance-review items on future committee agendas. One board member volunteered to help convene cross-board conversations with the Medical Board of California and other licensing boards to examine how to make prescriber contact more reliable during dispensing checks.

Public commenters and pharmacists told the board that stock shortages and insurer policies (including medical-benefit billing for long-acting injectable products) add administrative burdens that reduce pharmacies' ability to dispense promptly. A pharmacist working in an FQHC said that Medicare and insurer billing rules have forced clinics to buy medication up front or to develop specialized billing workflows, which are not available to many community pharmacies.

Why it matters: Buprenorphine reduces overdose risk and is a cornerstone of opioid use disorder treatment. Presenters told the board that access can be interrupted by operational issues at the point of dispensing and by conservative application of pharmacy "red flags." The board has regulatory authority over pharmacist practice and guidance; members signaled they will pursue education and outreach rather than new enforcement actions.

What happens next: Board members asked staff to bring this topic to the board's committee structure for follow-up, recommended outreach to other licensing boards, and supported educational resources for pharmacists and prescribers. Several presenters offered technical assistance for an education campaign the board may sponsor.